These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Restellini S; Khanna R; Afif W Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272 [TBL] [Abstract][Full Text] [Related]
8. The role of biologics in the treatment of patients with inflammatory bowel disease. Selinger CP; Carbery I; Al-Asiry J Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary. Mountifield R J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():25-26. PubMed ID: 33817852 [No Abstract] [Full Text] [Related]
10. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. Dutt K; Vasudevan A Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538 [No Abstract] [Full Text] [Related]
11. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Mitrev N; Leong RW Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765 [TBL] [Abstract][Full Text] [Related]
12. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment? Hoseyni H; Xu Y; Zhou H J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502 [TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Hemperly A; Sandborn WJ; Vande Casteele N Inflamm Bowel Dis; 2018 Nov; 24(12):2527-2542. PubMed ID: 29788338 [TBL] [Abstract][Full Text] [Related]
15. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Conrad MA; Kelsen JR Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562 [TBL] [Abstract][Full Text] [Related]
16. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Gisbert JP; Chaparro M J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929 [TBL] [Abstract][Full Text] [Related]
17. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576 [No Abstract] [Full Text] [Related]
18. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Papamichael K; Cheifetz AS Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757 [TBL] [Abstract][Full Text] [Related]
20. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD. Abreu MT Dig Dis Sci; 2019 Dec; 64(12):3377-3381. PubMed ID: 31628571 [No Abstract] [Full Text] [Related] [Next] [New Search]